Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) said it has aligned with the U.S. Food and Drug Administration on the regulatory pathway for CRB-701, its Nectin-4–targeting antibody-drug conjugate ...

Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients ...

Neoadjuvant chemoimmunotherapy demonstrated high pathological response rates with “manageable” toxicity in patients with squamous cell lung cancer, according to data presented at European Lung Cancer ...

Cervical squamous cell carcinoma is one of the predominant histological subtypes of cervical cancer, with significant morbidity and mortality globally. Its management increasingly relies on the ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) ...

A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth ...

The head and neck squamous cell carcinoma market is experiencing significant growth, with its size projected to ...

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

The global recurrent head and neck cancer squamous cell carcinoma market is experiencing robust growth, projected to expand from $3.32 billion in 2025 to $3.55 billion in 2026 at ...